Roche's Tecentriq cocktail boosts survival in small cell lung cancer
ZURICH (Reuters) - Swiss drugmaker Roche said on Monday that a cocktail of its immunotherapy Tecentriq with chemotherapy boosted survival of patients with previously untreated extensive-stage small cell lung cancer compared with chemotherapy alone.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Immunotherapy | Lung Cancer | Switzerland Health